American Regent vs. Hikma: Selenium Formulation Patent Case Consolidated in NJ

Case Overview

The Parties

The Patent at Issue

The patent in dispute — **U.S. Patent No. US12150957B2** (Application No. US18/672876) — covers selenious acid formulations for intravenous administration, specifically addressing selenium concentration in injectable solutions. This patent falls within the pharmaceutical formulation and trace element supplementation technology area.

• • US12150957B2 — Selenious acid formulations for intravenous administration.

The Accused Products

The accused products are selenious acid injectable formulations presented in three distinct configurations:

• • 600 mcg Selenium / 10 mL (equivalent to 60 mcg Selenium/mL)
• • 60 mcg Selenium / mL (equivalent to 60 mcg Selenium/mL)
• • 12 mcg Selenium / 2 mL (equivalent to 6 mcg Selenium/mL)

These selenium concentrations are clinically significant in parenteral nutrition, where trace element supplementation is tightly regulated and dosage precision is critical.

Legal Representation

American Regent was represented by attorneys **Charles H. Chevalier** and **Christine A. Gaddis** of **Gibbons PC**, a well-regarded New Jersey-based law firm with an established pharmaceutical and IP litigation practice. Defendant agent and law firm information was not disclosed in the available case record.

Litigation Timeline & Procedural History

The District of New Jersey is a strategically significant venue for pharmaceutical patent litigation. As home to a dense concentration of pharmaceutical and life sciences companies, it is one of the most active federal districts for Hatch-Waxman ANDA patent disputes in the United States.

The case reached resolution in a remarkably compressed timeframe of **21 days**, which is characteristic of a procedural disposition rather than substantive adjudication. No trial, claim construction hearing, or dispositive motion appears to have been reached during this period. The basis of termination was **case consolidation**, meaning this action was merged into a related or lead consolidated proceeding — a common practice in multi-defendant ANDA litigation where plaintiffs assert the same patents against multiple generic filers.

No chief judge designation was noted in the available case record.

The Verdict & Legal Analysis

Outcome

This case did not produce a merits verdict, damages award, or injunctive relief ruling. The formal disposition reflects consolidation into a broader coordinated action. Per the case record, the governing order directed that: “all filings in the Consolidated Action shall continue use the following caption going forward.”

Specific damages were not disclosed, and no findings on infringement or patent validity were issued in this individual docket.

Verdict Cause Analysis

The infringement action was brought under the pharmaceutical patent infringement framework, most likely implicating 35 U.S.C. § 271(e)(2), the Hatch-Waxman provision that treats the filing of an ANDA referencing a patented drug as an act of infringement. This statutory mechanism is specifically designed to adjudicate patent disputes before a generic product reaches market, making early consolidation a logical and efficient approach when multiple ANDAs challenge the same patent.

Consolidation at this stage suggests that American Regent may have filed parallel actions against multiple generic applicants — a standard Hatch-Waxman litigation strategy. By consolidating these actions, the court enables uniform claim construction, coordinated discovery, and consistent judicial management across all defendant parties challenging U.S. Patent No. US12150957B2.

Legal Significance

While this case produced no precedential ruling on patent validity or infringement, its procedural posture carries strategic weight:

• • Claim Construction Pending: Because the case was consolidated rather than dismissed, the substantive questions of infringement and validity remain live in the consolidated proceeding. Future rulings in that action will carry greater precedential significance.
• • Patent Scope of US12150957B2: The patent’s claims covering specific selenium concentration configurations in injectable formulations are likely to face scrutiny under claim construction principles, with Hikma likely to challenge whether its ANDA product falls within the literal scope or under the doctrine of equivalents.
• • Obviousness and Prior Art: Selenium formulations for parenteral use have an established prior art landscape. Validity challenges under 35 U.S.C. § 103 (obviousness) are foreseeable in the consolidated proceedings.

Strategic Takeaways

For Patent Holders (Brand Pharmaceutical Companies):

• • Early consolidation of multi-defendant Hatch-Waxman cases can streamline enforcement while preserving claim strength across all ANDA challenges.
• • Ensuring patent claims include specific concentration limitations — as seen in US12150957B2 — can create defensible, narrow claim sets that are harder to design around.

For Accused Infringers (Generic Manufacturers):

• • Consolidation does not eliminate individual defenses. Hikma and any co-defendants retain the ability to advance distinct non-infringement and invalidity arguments.
• • Early evaluation of design-around opportunities — such as alternative selenium concentrations outside claimed ranges — remains a viable risk mitigation strategy.

For R&D Teams:

• • Freedom-to-operate (FTO) analysis for injectable trace element formulations must account for recently issued formulation patents such as US12150957B2, particularly where concentration specifications are precisely claimed.

Q: What patent is involved in American Regent v. Hikma Pharmaceuticals?
U.S. Patent No. US12150957B2 (Application No. US18/672876), covering selenious acid injectable formulations at specific selenium concentrations.

Q: Why was Case No. 2:24-cv-11118 closed after only 21 days?
The case was closed due to consolidation into a related coordinated action — a common procedural outcome in multi-defendant pharmaceutical patent litigation, not a merits resolution.

Q: How does this case affect selenious acid patent litigation broadly?
The consolidated proceeding will ultimately determine infringement and validity of US12150957B2, establishing precedent for how selenium concentration claims are construed in injectable formulation patents.